Efficacy of celastrol combined with cisplatin in enhancing the apoptosis of U‑2OS osteosarcoma cells via the mitochondrial and endoplasmic reticulum pathways of apoptosis

Authors:

Abstract
Osteosarcoma is a common primary malignant tumor of bone, and the poor prognosis and low 5‑year survival rate have not improved for three decades. The present study aimed to study the effect a combination of celastrol and cisplatin on the human osteosarcoma cell line U‑2OS, and to investigate the mechanism by which celastrol/cisplatin induces the apoptosis of osteosarcoma cells. MTT and Annexin V‑FITC/PI assays were used to evaluate the effects of combined celastrol/cisplatin on growth and apoptosis, respectively, in U‑2OS cells. Morphological changes accompanying cell growth inhibition were observed using a fluorescence microscope. Combination index (CI) analysis was used to evaluate the combinatorial effects of celastrol/cisplatin treatment. Western blotting was used to quantify the expression of apoptosis‑associated proteins. It was identified that celastrol/cisplatin inhibited the growth of U‑2OS cells in a dose‑dependent manner. CI analysis revealed that combined celastrol/cisplatin demonstrated a synergistic effect in U‑2OS cells, with CIs ranging from 0.80 to 0.97 at effect levels from IC10 to IC70. In addition, it was observed that celastrol/cisplatin upregulated the expression of Bcl‑associated X protein, cytochrome c, caspase‑3 and C/EBP homologous protein, and downregulated the expression of Bcl‑2, poly(ADP‑ribose) polymerase, 78 kDa glucose‑regulated protein and caspase‑9, whereas the expression of caspase‑8 remained unchanged. To conclude, celastrol/cisplatin induced apoptosis in U‑2OS cells via the mitochondrial and endoplasmic reticulum pathways, particularly in the former. Celastrol/cisplatin therefore exhibits potential as a novel therapeutic combination for the treatment of osteosarcoma.

This publication has 34 references indexed in Scilit: